Evidence map›Paper›PMID 34098977›Full record

ArticleRadiation oncology (London, England)2021

Outcomes with multi-disciplinary management of central lung tumors with CT-guided percutaneous high dose rate brachyablation.

Stephanie M Yoon, Robert Suh, Fereidoun Abtin, Drew Moghanaki, Scott Genshaft, Mitchell Kamrava, Alexandra Drakaki, Sandy Liu, Puja Venkat, Alan Lee and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiation oncology (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Stephanie M YoonDepartment of Radiation Oncology, University of California Los Angeles, 200 Medical Plaza Driveway, Suite B265, Los Angeles, CA, 90095, USA.
Robert SuhDepartment of Radiology Thoracic Interventional Services, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Fereidoun AbtinDepartment of Radiology Thoracic Interventional Services, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Drew MoghanakiDepartment of Radiation Oncology, University of California Los Angeles, 200 Medical Plaza Driveway, Suite B265, Los Angeles, CA, 90095, USA.
Scott GenshaftDepartment of Radiology Thoracic Interventional Services, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Mitchell KamravaDepartment of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Alexandra DrakakiDepartment of Hematology and Medical Oncology, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Sandy LiuDepartment of Hematology and Medical Oncology, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Puja VenkatDepartment of Radiation Oncology, University of California Los Angeles, 200 Medical Plaza Driveway, Suite B265, Los Angeles, CA, 90095, USA.
Alan LeeDepartment of Radiation Oncology, University of California Los Angeles, 200 Medical Plaza Driveway, Suite B265, Los Angeles, CA, 90095, USA.
Albert J ChangDepartment of Radiation Oncology, University of California Los Angeles, 200 Medical Plaza Driveway, Suite B265, Los Angeles, CA, 90095, USA. AJChang@mednet.ucla.edu.ORCID http://orcid.org/0000-0002-4916-5047
University of California, Los Angeles · USCedars-Sinai Medical Center · USWest Los Angeles College · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCentrally located lung tumors present treatment challenges given their proximity to mediastinal structures including the central airway, esophagus, major vessels, and heart. Therapeutic options can be limited for medically inoperable patients, particularly if they have received previous thoracic radiotherapy. High dose rate (HDR) brachyablation was developed to improve the therapeutic ratio for patients with central lung tumors. The purpose of this study is to report initial safety and efficacy outcomes with this treatment for central lung malignancies.

methodsFrom September 2015 to August 2019, a total of 25 patients with 37 pulmonary tumors were treated with percutaneous HDR brachyablation. Treatment was delivered by a multi-disciplinary team of interventional radiologists, pulmonologists, and radiation oncologists. Twenty-three patients received a median dose of 21.5 Gy (range 15-27.5) in a single fraction, whereas two patients received median dose of 24.75 Gy (range 24-25.5) over 2-3 fractions. Tumor local control (LC) was evaluated by Response Evaluation Criteria in Solid Tumors v1.1. Treatment-related toxicities were graded by Common Terminology Criteria for Adverse Events v5.0, with adverse events less than 90 days defined as acute, and those occurring later were defined as late. LC, progression-free survival (PFS), and overall survival (OS) rates were estimated by the Kaplan-Meier method.

resultsOf 37 treated tumors, 88% were metastatic. Tumor location was central and ultra-central in 24.3% and 54.1%, respectively. Average tumor volume was 11.6 cm

conclusionPercutaneous HDR brachyablation is a safe and promising treatment option for centrally located primary and metastatic lung tumors. Future comparisons with stereotactic body radiotherapy and other ablative techniques are warranted to expand multi-disciplinary management options.

Indexed as

AgedBrachytherapyFemaleHumansLung NeoplasmsMaleMiddle AgedProgression-Free SurvivalRadiation Dose HypofractionationRadiation InjuriesRadiotherapy, Image-GuidedRetrospective StudiesSurvival RateTomography, X-Ray ComputedBrachyablationBrachytherapyHigh-dose-rate brachytherapyInterstitial brachytherapyPulmonary metastasis

Identifiers

PMID34098977
PMCPMC8186067
OpenAlexW3170624809

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.